The aim of this study was to evaluate the usefulness of salmon calcitonin (sCT) in preventing corticosteroid-induced osteoporosis. Three groups of patients with sarcoidosis requiring long-term steroid therapy were followed for 2 years with yearly evaluations of vertebral cancellous mineral content (VCMC) by quantitative computed tomography. The first group (n = 18) was treated with intramuscular (i.m.) sCT for the 2-year study period; the second (n = 11) with i.m. sCT for the first 4 months and then with sCT nasal spray for 20 months; the third (n = 35) received no sCT. We observed a large mineral loss in the third group but a very slight drop of VCMC in the two groups receiving sCT. SCT nasal spray was better tolerated and as effective as i.m. injections. The action of sCT appeared extremely useful, especially in the first year of steroid therapy when corticosteroid-induced mineral loss was maximal. We conclude that sCT nasal spray is a good tool for preventing corticosteroid-induced osteoporosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02565124 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corticosteroid-induced bradycardia following high-dose methylprednisolone administration: a case report.
Ann Med Surg (Lond)
October 2024
Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, University of Aleppo, Aleppo, Syria.
Article Synopsis
- Corticosteroids, although effective in treating inflammation and modifying immune responses, can lead to several side effects like high blood sugar, hypertension, and bradycardia (slow heart rate).
- A case study details a 43-year-old woman with multiple sclerosis who developed symptomatic bradycardia after receiving high doses of methylprednisolone, which resolved after 36 hours once the medication was stopped.
- While bradyarrhythmias like bradycardia are rare compared to tachyarrhythmias, they are important to monitor, and corticosteroid-induced bradycardia typically resolves on its own and often occurs without clear reasons.
Beneath the Surface: Exploring Hidden Threats of Long-Term Corticosteroid Therapy to Bone Density.
Cureus
February 2024
General Practice, Alaziziyah Primary Health Care Center, Tabuk, SAU.
Within the field of medical treatments, corticosteroids are potent substances that efficiently reduce inflammation and immunological responses, making them essential for the management of a wide range of medical ailments. However, continued use of these synthetic drugs presents a serious risk: the onset of osteoporosis brought on by corticosteroids. Determining the complex pathways by which corticosteroids cause a general disturbance in bone metabolism, suppress osteoblast function, increase osteoclast activity, and upset the delicate balance of bone remodelling emphasizes the need for all-encompassing management and prevention approaches.
View Article and Find Full Text PDFNationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users.
SAGE Open Med
March 2024
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Objectives: Glucocorticoid steroids are frequently prescribed, and side effects are well-known, such as glucocorticoid-induced osteoporosis. Our aim was to estimate the nationwide trend in the prevalence of glucocorticoid steroid prescriptions over 17 years and to elucidate the proportion of patients on long-term glucocorticoid steroid therapy who receive active bone protective therapy. As well as to examine which medical specialties prescribe glucocorticoid steroids the most.
View Article and Find Full Text PDFGamma-aminobutyric acid (GABA)-mediated bone formation and its implications for anti-osteoporosis strategies: Exploring the relation between GABA and GABA receptors.
Biochem Pharmacol
December 2023
Department of Marine Life Science, Jeju National University, Jeju 63243, Republic of Korea. Electronic address:
Osteoporosis is a significant global health concern, linked to reduced bone density and an increased fracture risk, with effective treatments still lacking. This study explored the potential of gamma-aminobutyric acid (GABA) and its receptors as a novel approach to promote osteogenesis and address osteoporosis. GABA concentrations up to 10 mM were well-tolerated by MC3T3-E1 preosteoblast, stimulating osteoblast differentiation and mineralization in a concentration- and time-dependent manner.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!